Inovio Pharmaceuticals (NASDAQ:INO) Releases Earnings Results, Beats Expectations By $0.02 EPS

Inovio Pharmaceuticals (NASDAQ:INO) announced its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.02, FiscalAI reports.

Here are the key takeaways from Inovio Pharmaceuticals’ conference call:

• Inovio said its INO-3107 BLA remains on track for the October 30, 2026 PDUFA date, and the FDA’s mid-cycle review raised no new significant issues. Management also said the agency reiterated plans to schedule the informal meeting on accelerated-approval eligibility.
• The company continues to believe INO-3107 supports accelerated approval based on its phase I/II data, citing large reductions in surgeries, a favorable safety profile, and a differentiated mechanism that may help patients not served by the current approved therapy.
• Inovio is building commercial readiness ahead of a potential launch, including partnerships for logistics, specialty distribution, pharmacy, and patient support. Management said it plans to commercialize with a contract sales organization and expects to benefit from learnings from the competitor’s launch.
• The company strengthened its balance sheet with a April equity offering that raised about $16 million net. Inovio ended Q1 with $37.7 million in cash and short-term investments and said its runway now extends into Q1 2027, beyond the expected PDUFA date.
• Beyond INO-3107, Inovio highlighted progress on its broader pipeline, including an Akeso/Dana-Farber collaboration in glioblastoma and advancement of its DPROT platform for rare-disease applications such as hemophilia A, Fabry disease, and hypophosphatasia.

Inovio Pharmaceuticals Stock Performance

Shares of NASDAQ INO traded down $0.06 during midday trading on Wednesday, reaching $1.36. The stock had a trading volume of 3,483,792 shares, compared to its average volume of 2,000,902. The stock has a 50-day moving average of $1.40 and a 200-day moving average of $1.72. Inovio Pharmaceuticals has a 12-month low of $1.03 and a 12-month high of $2.98. The company has a market capitalization of $94.09 million, a price-to-earnings ratio of -0.81 and a beta of 1.43.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Focus Partners Wealth bought a new position in shares of Inovio Pharmaceuticals during the third quarter worth $33,000. Raymond James Financial Inc. boosted its position in shares of Inovio Pharmaceuticals by 4,396.0% during the third quarter. Raymond James Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 16,309 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in shares of Inovio Pharmaceuticals during the third quarter worth $41,000. Zacks Investment Management bought a new position in shares of Inovio Pharmaceuticals during the third quarter worth $46,000. Finally, Caitong International Asset Management Co. Ltd boosted its position in shares of Inovio Pharmaceuticals by 752.9% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 20,572 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 18,160 shares during the last quarter. Institutional investors own 26.79% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on INO. Oppenheimer reissued an “outperform” rating on shares of Inovio Pharmaceuticals in a research note on Friday, March 13th. Weiss Ratings cut shares of Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. Finally, Wall Street Zen raised shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $6.75.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.